A Rare Case of Small Cell Lung Cancer With an Epidermal Growth Factor Receptor Mutation and Its Response to...

Area of Science:

• Oncology
• Medical Genetics

Background:

• Small cell lung cancer (SCLC) is a distinct subtype of lung cancer, comprising less than 15% of all cases.
• Epidermal growth factor receptor (EGFR) mutations are uncommon in SCLC, unlike in non-small cell lung cancer (NSCLC).
• EGFR tyrosine kinase inhibitors (TKIs) like osimertinib are standard first-line treatments for metastatic NSCLC harboring EGFR mutations.

Observation:

• A 63-year-old female presented with metastatic SCLC.
• Genetic analysis revealed the presence of an EGFR mutation in the tumor.
• The patient received treatment with osimertinib, a third-generation EGFR TKI.

Findings:

• The case represents a rare instance of EGFR-positive SCLC.
• The patient's response to osimertinib treatment in the context of SCLC was evaluated.
• This case provides initial insights into the potential efficacy of EGFR TKIs in a subset of SCLC patients.

Implications:

• This finding suggests that a small fraction of SCLC cases may harbor actionable EGFR mutations.
• Osimertinib may represent a potential therapeutic option for SCLC patients with specific EGFR alterations.
• Further research is warranted to explore the prevalence and clinical significance of EGFR mutations in SCLC and the role of targeted therapies.